A recent study published in Public Understanding of Science has shed light on how retractions of scientific papers, intended ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK ...

DMU will be part of a consortium laying the foundation for future medicines that are affordable, safe, effective, and ...

Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

The USAN designation reflects Okyo Pharma's commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix "-mod” in urcosimod denotes its classification as a modulator of ...

Triple click chemistry has revolutionized chemical synthesis with its simplicity and efficiency, allowing for the quick and selective assembly of complex molecules. Now, in a recent study, researchers ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.